What to ask about orthobiologics cost before you book

What to understand before you ask the price

When a clinic says orthobiologics, it means shots made from body material instead of a usual drug. PRP stands for platelet-rich plasma, made by drawing blood and spinning it until platelets collect in one part of the liquid.

That liquid is used for the shot, while concentrated PRP gathers more platelets in it. The names matter because the work and price may differ.

There isn't a dependable published price for this care in Surprise. You'll need a quote for the exact shot being discussed.

What to get in writing

Ask for one written total before you book any care. It needs to name the shot, planned visits, exam costs, and added follow-up charges.

Ask whether you'll owe more if the first treatment doesn't help. That can spare you a second bill you hadn't planned for.

Keep the quote and read it at home without anyone waiting. If the total isn't clear, don't set a date yet.

What to ask when the aching won't settle

Most biologic therapies, which means body-material shots such as prepared blood, must usually be paid from your own pocket even when the exam or X-ray is covered by insurance. Coverage may still be available for exercise, physical therapy, or a cortisone shot.

At QC Kinetix, a medical provider is the clinician who checks the joint and reviews your health. You'll hear why one choice may fit, what isn't known, and what the full care may cost.

The visit may cover knee or hip surgery alternatives, meaning care to consider before an operation. A plan's denial only says it won't pay; it doesn't say whether the care will help.

Sources

1. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446; 95% CI $4,550-5,762, n=65) and the mean claimed clinical efficacy was 82% (SD 9.6%; n=36) - a figure the authors describe as a gap between marketing claims and the published literature.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. Journal of Knee Surgery, 2018. DOI: 10.1055/s-0037-1604443.

2. An analysis of internet-based marketing claims found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the UNITED STATES - previously treated as a phenomenon of countries with lax medical regulation - and concluded that regulatory agencies must better oversee this marketplace.

   Turner L, Knoepfler P. — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

3. In January 2025 federal district court orders resolving a joint FTC and Georgia Attorney General complaint permanently BANNED the co-founders of the Stem Cell Institute of America and several related companies from marketing stem cell therapy, and required payment of $5,155,146 in civil penalties and consumer refunds. In March 2024 the court had granted summary judgment on all counts, finding the defendants created and published false and misleading advertisements about the efficacy of stem cell injections. The affiliated clinic charged up to $5,000 per injection, almost exclusively to elderly and disabled consumers.

   Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. FTC Press Release, 2025.

4. A meta-analysis and metaregression of 14 RCTs (978 patients) of dextrose prolotherapy for knee OA found favourable effects on pain, global function and quality of life versus placebo injection and non-invasive control, and effects COMPARABLE to other invasive therapies at each follow-up duration - with the authors cautioning that heterogeneity and risk of bias across the included trials require the results to be interpreted cautiously.

   Chen YW, et al. — Effectiveness, Compliance, and Safety of Dextrose Prolotherapy for Knee Osteoarthritis: A Meta-Analysis and Metaregression of Randomized Controlled Trials.. Clinical Rehabilitation, 2022. DOI: 10.1177/02692155221086213.

5. The 2015 Annals network meta-analysis of 137 studies (33,243 participants) compared oral and injected drugs for knee OA and found ALL interventions significantly outperformed oral placebo for pain, with intra-articular hyaluronic acid the most efficacious (effect size 0.63) and acetaminophen the least (0.18). Intra-articular treatments outperformed NSAIDs, which the authors noted may partly reflect the integrated effect of the injection process itself.

   Bannuru RR, et al. — Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.. Annals of Internal Medicine, 2015. DOI: 10.7326/M14-1231.

6. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.